Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate.
Thao TangQuy LeSommer CastroLaura PardoCyd Nourigat McKayLaKeisha PerkinsJenny SmithDanielle C KirkeyCristina AbrahamsKristin BedardArturo MolinaLisa Eidenshinck BrodersenMichael R LokenKatherine TarlockSoheil MeshinchiKeith R LoebPublished in: Blood advances (2022)